STEP-HFpEF
2023
Semaglutide Treatment Effect in People with obesity and HFpEF
In 529 patients with HFpEF (EF ≥ 45%) and obesity (BMI ≥ 30) without diabetes, semaglutide 2.4 mg improved heart-failure symptoms (KCCQ) and body weight compared with placebo.
Result
Primary endpoint: Dual primary: change in KCCQ Clinical Summary Score and percentage change in body weight at 52 weeks
KCCQ-CSS +16.6 vs +8.7 (difference 7.8 points, 95% CI 4.8-10.9; P<0.001); body weight -13.3% vs -2.6% (difference -10.7 points, 95% CI -11.9 to -9.4; P<0.001).
- Subtopic
- GLP-1 RA
- Design
- Double-blind placebo-controlled RCT
- Relevance
- Important: one of several pillars.
- Cited in
- ESC 2026 HFACC/AHA 2026 CKM
- Source
- Kosiborod MN, et al. N Engl J Med. 2023;389(12):1069-1084.doi 10.1056/NEJMoa2306963
Discussion & critique
Symptom/weight surrogate endpoints in non-diabetic patients over one year, not powered for HF events. Reframed obesity-phenotype HFpEF as a treatable cardiometabolic disease and drove GLP-1 agonists into HFpEF management.